Lung Cancer Screening Program Leadership & Staff | NYU Langone Health
Perlmutter Cancer Center’s Lung Cancer Screening Program leadership and staff provide guidance on screenings and help coordinate appointments.
Lung Transplant Program | NYU Langone Health
Experts at the Lung Transplant Program at NYU Langone Transplant Institute perform lung transplants and pulmonary thromboendarterectomy.
Lung Transplant Program Doctors | NYU Langone Health
Find a doctor at the Lung Transplant Program at NYU Langone.
Lupus Center | NYU Langone Health
NYU Langone’s Lupus Center connects patients with advanced treatments that can help reduce symptoms.
Lupus Center Doctors | NYU Langone Health
Find a doctor at the Lupus Center at NYU Langone.
Lupus in Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone prescribe medication to manage symptoms and prevent complications of lupus.
Lupus Omics Cutaneous Kidney Investigative Team: Kidney Project 1
The purpose of this study is to learn more about patients with lupus (“systemic lupus erythematosus” or “SLE”) who may have injury to their kidney, which is called lupus nephritis. The goal of this study is to understand how lupus starts in the kidneys and injures the kidneys early in the course of lupus nephritis. For this study, we will examine the kidney tissue of patients with lupus who have never had kidney involvement but now show early signs of kidney injury. The diagnosis of early kidney injury will be made through a kidney biopsy, as is done for all lupus patients suspected of having kidney involvement. To better understand early kidney injury, an extra sample of tissue will be obtained for research studies while you are having a kidney biopsy for clinical purposes.
Lupus Omics Cutaneous Kidney Investigative Team: Kidney Project 2
The purpose of this study is to learn more about patients with lupus (“systemic lupus erythematosus” or “SLE”) who may have injury to their kidney, which is called lupus nephritis. The goal of this study is to understand kidney injury and whether or not standard of care treatment is working. You will be asked to see your lupus physician for approximately 4 visits over the course of 1 year to help us assess lupus disease activity over time. You may have additional biopsies to help evaluate if standard of care treatment is working. Your physician will start additional treatment as part of your clinical care if it looks as though the standard of care treatment is not working.
Lupus Omics Cutaneous Kidney Investigative Team: Skin Project 1 and Skin Project 2
Cutaneous lupus erythematosus (CLE) includes three main subsets: acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE), the latter including discoid lupus erythematosus (DLE). Lesion progression may lead to significant scarring and dyspigmentation and overall, patients with CLE have poor quality of life with high levels of depression and anxiety. Differentiation of CLE subsets is largely based on clinical features. This study will allow to better understand the differential pathogenesis between CLE subsets which may help in appropriate diagnosis and impact treatments. In CLE, response to therapies is variable and unpredictable in conventional practice, and only 50% of CLE patients respond to the first-line therapy hydroxychloroquine leading to a delay in selecting appropriate treatment while increasing disease severity. Presently, the only way to identify response is by stepping through sequential therapies that can have a slow onset of action. Identifying differential molecular skin expression between responders and non-responders across CLE subsets may help in identifying responders to corresponding treatment and personalize management with the help of predictive markers. SP1: ACLE, SCLE and CCLE will be studied in a cross-sectional fashion. Treatment-naïve lesional and non-lesional skin biopsies, peripheral blood mononuclear cells (PBMCs) and other body fluids will be obtained. Comparisons of tissue omics between CLE subsets are expected to yield insights related to differential expression of cells and pathways.SP2: SCLE and CCLE (not ACLE) will be evaluated routinely every 3 months for 6 months. Patients enrolled in SP1 with these skin lesions may be enrolled in SP2 based on inclusion criteria. Clinical response of skin disease to standard of care therapies will be evaluated using the CLASI score. Lesional and non-lesional skin biopsies, PBMCs and other body fluids will be obtained at baseline and during follow up visits at 3-month intervals to determine differences in cells and pathways that account for the variation in response to therapies. Comparisons of serum, tissue omics and skin/stool/saliva microbiome between treatment response groups across CLE subsets are expected to yield several insights.
LVAD Program | NYU Langone Health
NYU Langone cardiac experts offer left ventricular assist device (LVAD) therapy to treat people with advanced heart failure.